ZTS
Zoetis Inc
Healthcare, Event Driven/Special Sit
06/29/2015
Presented
| Date | 06/24/2015 |
| Price | $55.38 |
| Market Cap | N/A |
| Ent Value | $30.80B |
| P/E Ratio | 47x |
| Book Value | N/A |
| Div Yield | 0.6% |
| Shares O/S | 499.96M |
| Ave Daily Vol | N/A |
| Short Int | 1.41% |
Current
| Price | $192.39 |
| Market Cap | $87.16B |
| Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines and vaccines for livestock and companion animals worldwide. The company operates through four segments: the United States; Europe/Africa/Middle East; Canada/Latin America; and Asia/Pacific. It offers anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; vaccines that are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; and parasiticides that prevent or eliminate external and internal parasites, such as fleas, ticks, and worms. The company also provides medicated feed additives that offer medicines to livestock; veterinarian solutions for anesthesia and treating pain and serious illnesses, such as diabetes; and other pharmaceutical products, including pain and sedation, oncology, antiemetic, allergy and dermatology, and reproductive products. In addition, it offers other product categories, such as nutritionals and agribusiness, as well as products and services in complementary areas, including diagnostics, genetics, biodevices, and services. The company markets its products to veterinarians and livestock producers through its sales representatives, and technical and veterinary operations specialists. Zoetis Inc. was founded in 1952 and is headquartered in Florham Park, New Jersey. |
Publicly traded companies mentioned herein: Abaxis Inc (ABAX), Actavis plc (ACT), Bayer AG (BAYN GR), Eli Lilly And Co (LLY), IDEXX Laboratories Inc (IDXX), Novartis AG (NVS), Pfizer Inc (PFE), Valeant Pharmaceuticals Intl Inc (VRX), Zoetis Inc (ZTS)
Highlights
The presenter is long shares of "optically expensive but potentially event driven" Zoetis (ZTS) and believes shares are attractive in the high $40s. The Chairman of Actavis, Paul Bisaro, was recently appointed to the company's Board of Directors and management has been under pressure from Bill Ackman of Pershing Square Capital to cut costs. In addition, the presenter outlined a number of items that he feels should be incremental to management’s "conservative" EPS guidance of $2.25 in 2017, and other factors that do not seem to be fully appreciated by the Street. Also, two years has now passed since the spin-off from Pfizer and a buyer could do a deal with ZTS without potentially causing tax issues.
◆Signing up and creating account with us unlocks this content for you. Contact us today for full access to DeMatteo Research and more.
◆Signing up and creating account with us unlocks this content for you. Contact us today for full access to DeMatteo Research and more.